



Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/751,736	
	Filing Date	January 6, 2004	
	First Named Inventor	R.V. MARTINEZ <i>et al.</i>	
	Group Art Unit	1642	
	Examiner Name	Lei Yao	
Total Number of Pages in This Submission	5	Attorney Docket Number	031896-002000 (AM100927)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s): PTO Form-1449 citing six (6) U.S. patent, six (6) foreign patent and thirty (30) non-patent literature documents and one (1) International Search Report
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (031896-002000) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Raymond Van Dyke, Registration No. 34,746 Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	November 2, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 703-746-4060.	
Date	Signature



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:)
Robert Vincent MARTINEZ *et al.*) Art Unit: 1642
Serial No.: 10/751,736) Examiner: Lei Yao
Filed: January 6, 2004) Confirmation No: 2977
For: COMPOSITIONS AND METHODS)
FOR DIAGNOSING AND TREATING)
COLON CANCERS)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98.

The instant Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97 (c) after a first office action on the merits but prior to the mailing date of a final office action, Notice of Allowance or an action that closes prosecution in the application.


In view of the Official Gazette Notice dated August 5, 2003, copies of the cited U.S. patent documents are not included with this Statement. However, copies of the cited foreign patent and non-patent literature documents, as well as the International Search Report from a related international patent application, are enclosed.

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. It is respectfully requested that an Examiner-initialed copy of this form be returned to the undersigned.


The Commissioner is hereby authorized to charge any fees connected with this filing, which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

Date: November 2, 2005

By: 
Raymond Van Dyke
Registration No. 34,746

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, D.C. 20004-2128
Telephone: (202) 585-8000
Facsimile: (202) 585-8080



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,736
				Filing Date	January 6, 2004
				First Named Inventor	R. V. MARTINEZ <i>et al.</i>
				Art Unit	1642
				Examiner Name	Lei Yao
Sheet	1	of	3	Attorney Docket Number	031896-002000 (AM100927)

U.S. PATENT DOCUMENTS					
Examiner Initials ⁵	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		U.S. - 5,965,403	07-06-1999	TULLIS, R. H.	
		U.S. - 6,506,559	01-14-2003	FIRE, A. <i>et al.</i>	
		U.S. - 4,554,101	11-19-1985	HOPP, T.P.	
		U.S. - 4,419,446	01-14-2003	FIRE, A. <i>et al.</i>	
		U.S. - 4,798,885	11-19-1985	HOPP, T.P.	
		U.S. - 5,141,905	10-17-1995	MODRICH, P. <i>et al.</i>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials ⁵	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ² (if known)				
		WO 03/009814 A2	02-06-2003	SCHLEGEL, R. <i>et al.</i>		
		WO 99/497354 A1	10-07-1999	KRUH, G. <i>et al.</i>		
		WO 04/016810 A2	02-26-2004	SCHWIDETZKY, U.		
		WO 03/104404 A2	12-18-2003	EBNER, R.		
		WO 02/079238 A2	10-10-2002	EULENBERG, K. <i>et al.</i>		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ⁵	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BURGER, M. J. <i>et al.</i> , Expression analysis of δ -catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer, <i>Int. J. Cancer</i> , 100(2):228-237, 2002	
		CHEN, Z.-S. <i>et al.</i> , Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4): MRP4 Is a Component of the Methotrexate Efflux System, <i>Cancer Res.</i> , 62:3144-3150, 2002	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,736
				Filing Date	January 6, 2004
				First Named Inventor	R. V. MARTINEZ <i>et al.</i>
				Art Unit	1642
				Examiner Name	Lei Yao
Sheet	2	of	3	Attorney Docket Number	031896-002000 (AM100927)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
		COLSTON, J. T. <i>et al.</i> , Ca ²⁺ channel alpha 1-subunit transcripts are differentially expressed in rat pheochromocytoma (PC12) cells following nerve growth factor treatment, <i>Int. J. Dev. Neurosci.</i> , 16(5):379-389, 1998		
		DJAMSHIDIAN, A. <i>et al.</i> , Altered expression of voltage-dependent calcium channel alpha(1) subunits in temporal lobe epilepsy with Ammon's horn sclerosis, <i>Neuroscience</i> , 111(1):57-69, 2002		
		EPSTEIN, L. H. <i>et al.</i> , Dopamine transporter genotype as a risk factor for obesity in African-American smokers, <i>Obes. Res.</i> , 10(12):1232-1240, 2002		
		FEIGELSTOCK, D. <i>et al.</i> , The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor, <i>J. Virol.</i> , 72(8):6621-6628, 1998		
		HONKE, K. <i>et al.</i> , Cancer-associated Expression of Glycolipid Sulfotransferase Gene in Human Renal Cell Carcinoma Cells, <i>Cancer Res.</i> , 58(17):3800-3805, 1998		
		ICHIMURA, T. <i>et al.</i> , Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury, <i>J. Biol. Chem.</i> , 273(7):4135-4142, 1998		
		KATSURA, M. <i>et al.</i> , Up-regulation of L-type voltage-dependent calcium channels after long term exposure to nicotine in cerebral cortical neurons, <i>J. Biol. Chem.</i> , 277(10):7979-7988, 2002		
		LAI, L. and TAN, T. M., Role of glutathione in the multidrug resistance protein 4 (MRP4/ABCC4)-mediated efflux of cAMP and resistance to purine analogues, <i>Biochem. J.</i> , 361(Pt. 3):497-503, 2002		
		LAUNAY, P. <i>et al.</i> , TRPM4 is a Ca ²⁺ -activated nonselective cation channel mediating cell membrane depolarization, <i>Cell</i> , 109(3):397-407, 2002		
		LERMAN, C. <i>et al.</i> , Evidence suggesting the role of specific genetic factors in cigarette smoking, <i>Health Psychol.</i> , 18(1):14-20, 1999		
		LOCKHART, D. J. <i>et al.</i> , Expression monitoring by hybridization to high-density oligonucleotide arrays, <i>Nat. Biotechnol.</i> , 14(13):1675-1680, 1996		
		MYERS, R. M. <i>et al.</i> , Detection of single base substitutions by ribonuclease cleavage at mismatches in RNA:DNA duplexes, <i>Science</i> , 230:1242-1246, 1985		
		RANALDI, G. <i>et al.</i> , Intracellular distribution of labile Zn(II) and zinc transporter expression in kidney and MDCK cells, <i>Am. J. Physiol. Renal Physiol.</i> , 283(6):F1365-F1375, 2002		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/751,736
				Filing Date	January 6, 2004
				First Named Inventor	R. V. MARTINEZ <i>et al.</i>
				Art Unit	1642
				Examiner Name	Lei Yao
Sheet	3	of	3	Attorney Docket Number	031896-002000 (AM100927)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		SEGMAN, R. H. <i>et al.</i> , Association between the dopamine transporter gene and posttraumatic stress disorder, <i>Mol. Psychiatry</i> , 7(8):903-907, 2002	
		SONG, E., RNA interference targeting Fas protects mice from fulminant hepatitis, <i>Nat. Med.</i> , 9(3):347-351, 2003	
		TENG, D. H. <i>et al.</i> , Mutation analyses of 268 candidate genes in human tumor cell lines, <i>Genomics</i> , 74(3):352-364, 2001	
		UTHOFF, S. M. <i>et al.</i> , T-cell receptor γ : a microsatellite marker for colorectal cancer, <i>Ann. Surg. Oncol.</i> , 9(1):88-93, 2002	
		VAN AUBEL, R. A. <i>et al.</i> , The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP, <i>J. Am. Soc. Nephrol.</i> , 13 (3):595-603, 2002	
		WYATT, C. N. <i>et al.</i> , Voltage-dependent binding and calcium channel current inhibition by an anti-alpha 1D subunit antibody in rat dorsal root ganglion neurones and guinea-pig myocytes, <i>J. Physiol.</i> , 502 (Pt 2):307-319, 1997, Erratum in: <i>J. Physiol. (Lond)</i> , 503(Pt 3):699, 1997	
		XU, L. L. <i>et al.</i> , PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer, <i>Cancer Res.</i> , 60(23):6568-6572, 2000	
		YAMADA, Y. <i>et al.</i> , Genomic variation in pancreatic ion channel genes in Japanese type 2 diabetic patients, <i>Diabetes Metab. Res. Rev.</i> , 17(3):213-216, 2001	
		YUAN, T. T. <i>et al.</i> , Cloning and genetic characterization of an evolutionarily conserved human olfactory receptor that is differentially expressed across species, <i>Gene</i> , 278(1-2):41-51, 2001	
		ZELCER, N. <i>et al.</i> , Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4), <i>Biochem. J.</i> , 371(Pt 2):361-367, 2003	
		Affymetrix GeneChip® Expression Analysis, Data Analysis Fundamentals	
		Affymetrix GeneChip® Expression Analysis, Technical Manual	
		PCR: A Practical Approach, McPherson, M. J. and Hames, B. D. (eds), IRL Press, at Oxford University Press, Inc., Oxford, England, 1991	
		PCR2: A Practical Approach, McPherson, M. J. and Hames, B. D. (eds), IRL Press, at Oxford University Press, Inc., Oxford, England, 1995	
		PCR Protocols: Current Methods and Applications, In: Methods in Molecular Biology, Vol. 15, White, Bruce Alan (ed.), Humana Press, Totowa, N.J. 1993	
		Partial International Search Report for PCT/US2004/015645, mailed 10/25/2005, 2 pages	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.